414 related articles for article (PubMed ID: 31143509)
1. Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma.
Bommareddy PK; Zloza A; Rabkin SD; Kaufman HL
Oncoimmunology; 2019; 8(7):1591875. PubMed ID: 31143509
[TBL] [Abstract][Full Text] [Related]
2. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
[TBL] [Abstract][Full Text] [Related]
3. Nectin-1 Expression Correlates with the Susceptibility of Malignant Melanoma to Oncolytic Herpes Simplex Virus In Vitro and In Vivo.
Schwertner B; Lindner G; Toledo Stauner C; Klapproth E; Magnus C; Rohrhofer A; Gross S; Schuler-Thurner B; Öttl V; Feichtgruber N; Drexler K; Evert K; Krahn MP; Berneburg M; Schmidt B; Schuster P; Haferkamp S
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34205379
[TBL] [Abstract][Full Text] [Related]
4. OncoVEX
Estrada J; Zhan J; Mitchell P; Werner J; Beltran PJ; DeVoss J; Qing J; Cooke KS
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37164449
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral Immunotherapy-Update 2019.
Hamid O; Ismail R; Puzanov I
Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
[TBL] [Abstract][Full Text] [Related]
6. Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma.
Bommareddy PK; Patel A; Hossain S; Kaufman HL
Am J Clin Dermatol; 2017 Feb; 18(1):1-15. PubMed ID: 27988837
[TBL] [Abstract][Full Text] [Related]
7. Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy.
Kohlhapp FJ; Kaufman HL
Clin Cancer Res; 2016 Mar; 22(5):1048-54. PubMed ID: 26719429
[TBL] [Abstract][Full Text] [Related]
8. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
Andtbacka RH; Kaufman HL; Collichio F; Amatruda T; Senzer N; Chesney J; Delman KA; Spitler LE; Puzanov I; Agarwala SS; Milhem M; Cranmer L; Curti B; Lewis K; Ross M; Guthrie T; Linette GP; Daniels GA; Harrington K; Middleton MR; Miller WH; Zager JS; Ye Y; Yao B; Li A; Doleman S; VanderWalde A; Gansert J; Coffin RS
J Clin Oncol; 2015 Sep; 33(25):2780-8. PubMed ID: 26014293
[TBL] [Abstract][Full Text] [Related]
9. Talimogene Laherparepvec: Moving From First-In-Class to Best-In-Class.
Kaufman HL; Shalhout SZ; Iodice G
Front Mol Biosci; 2022; 9():834841. PubMed ID: 35274007
[TBL] [Abstract][Full Text] [Related]
10. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.
Harrington KJ; Puzanov I; Hecht JR; Hodi FS; Szabo Z; Murugappan S; Kaufman HL
Expert Rev Anticancer Ther; 2015; 15(12):1389-403. PubMed ID: 26558498
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the oncolytic activity of a replication-competent and a replication-deficient herpes simplex virus 1.
Lindner G; Walter A; Magnus CL; Rosenhammer K; Holoborodko B; Koch V; Hirsch S; Grossmann L; Li S; Knipe DM; DeLuca N; Schuler-Thurner B; Gross S; Schwertner B; Toelge M; Rohrhofer A; Stöckl S; Bauer RJ; Knoll G; Ehrenschwender M; Haferkamp S; Schmidt B; Schuster P
Immunology; 2024 Jun; 172(2):279-294. PubMed ID: 38444199
[TBL] [Abstract][Full Text] [Related]
12. Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma.
Ferrucci PF; Pala L; Conforti F; Cocorocchio E
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33803762
[TBL] [Abstract][Full Text] [Related]
13. MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation.
Bommareddy PK; Aspromonte S; Zloza A; Rabkin SD; Kaufman HL
Sci Transl Med; 2018 Dec; 10(471):. PubMed ID: 30541787
[TBL] [Abstract][Full Text] [Related]
14. Talimogene Laherparepvec: An Oncolytic Virus Therapy for Melanoma.
Corrigan PA; Beaulieu C; Patel RB; Lowe DK
Ann Pharmacother; 2017 Aug; 51(8):675-681. PubMed ID: 28351167
[TBL] [Abstract][Full Text] [Related]
15. Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers.
Grigg C; Blake Z; Gartrell R; Sacher A; Taback B; Saenger Y
Semin Oncol; 2016 Dec; 43(6):638-646. PubMed ID: 28061981
[TBL] [Abstract][Full Text] [Related]
16. In vitro Characterization of Enhanced Human Immune Responses by GM-CSF Encoding HSV-1-Induced Melanoma Cells.
Delic M; Boeswald V; Goepfert K; Pabst P; Moehler M
Onco Targets Ther; 2022; 15():1291-1307. PubMed ID: 36310770
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic Herpes Simplex Virus Type 1 Induces Immunogenic Cell Death Resulting in Maturation of BDCA-1
Kalus P; De Munck J; Vanbellingen S; Carreer L; Laeremans T; Broos K; Dufait I; Schwarze JK; Van Riet I; Neyns B; Breckpot K; Aerts JL
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563257
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic viral kinetics mechanistic modeling of Talimogene Laherparepvec (T-VEC) a first-in-class oncolytic viral therapy in patients with advanced melanoma.
Ahamadi M; Kast J; Chen PW; Huang X; Dutta S; Upreti VV
CPT Pharmacometrics Syst Pharmacol; 2023 Feb; 12(2):250-260. PubMed ID: 36564918
[TBL] [Abstract][Full Text] [Related]
19. Talimogene laherparepvec (T-VEC) as cancer immunotherapy.
Kohlhapp FJ; Zloza A; Kaufman HL
Drugs Today (Barc); 2015 Sep; 51(9):549-58. PubMed ID: 26488034
[TBL] [Abstract][Full Text] [Related]
20. Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma.
Johnson DB; Puzanov I; Kelley MC
Immunotherapy; 2015; 7(6):611-9. PubMed ID: 26098919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]